The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Gene Review

Hsp84-2  -  heat shock protein, 2

Mus musculus

Synonyms: 84kDa, Hsp90, hsp2
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Hsp84-2

  • When administered in vivo to mice bearing MDA-MB-468 human breast cancer xenografted tumors, these agents result in pharmacologically relevant concentrations and, accordingly, in modulation of Hsp90-client proteins in tumors [1].
  • Characterization of heat-inducible expression and cloning of HtpG (Hsp90 homologue) of Porphyromonas gingivalis [2].

High impact information on Hsp84-2

  • Modulating molecular chaperone Hsp90 functions through reversible acetylation [3].
  • Molecular chaperone heat shock protein 90beta (Hsp90beta)-bound Ack1 and treatment of cells with geldanamycin, a Hsp90 inhibitor, inhibited Ack1 kinase activity and suppressed tumorigenesis [4].
  • Its Hsp90 inhibition results in multiple anti-tumor-specific effects, such as degradation of Hsp90-client proteins involved in cell growth, survival, and specific transformation, inhibition of cancer cell growth, delay of cell cycle progression, induction of morphological and functional changes, and apoptosis [5].
  • A role for the Hsp90 molecular chaperone family in antigen presentation to T lymphocytes via major histocompatibility complex class II molecules [6].
  • The PU-class, a purine-scaffold Hsp90 inhibitor series, has been reported to be potent and selective against Hsp90 both in vitro and in vivo models of cancer [1].

Biological context of Hsp84-2

  • These results show that Hsp90 can function at different levels within apoptotic signal transduction pathways [7].
  • Pharmacological inhibition of Hsp90 activity in IFN-gamma-treated APC resulted in severe abrogation of MHCII-restricted presentation of cytosolic antigen, but only partially inhibited exogenous antigen presentation [6].
  • The structure-activity relationship and selectivity for tumor Hsp90 of compounds within the series is presented [1].
  • For example, Hsp90 homologues in several microbial species have been shown to contribute to virulence [2].
  • Further, pharmacological Hsp90 inhibition reduced, while retroviral Hsp90 overexpression enhanced, the levels of stable compact MHCII heterodimers correlating with the antigen presentation phenotype [6].

Anatomical context of Hsp84-2


Associations of Hsp84-2 with chemical compounds

  • Furthermore, disrupting the function of Hsp90 by the addition of its specific inhibitor, geldanamycin, blocked Hsp90's protection of Bid cleavage [7].
  • One of such inhibitors, the purine-scaffold class, has been reported to be potent and selective against Hsp90 both in vitro and in vivo models of cancer [10].
  • It represents a class of drugs, the benzoquinone ansamycin antibiotics, capable of binding and disrupting the function of Hsp90, leading to the depletion of multiple oncogenic client proteins [11].
  • In the absence of Hsp90 inhibitors, NAC stimulated the activation of MAP kinase in BCR-ABL-transformed but not in the parental Rat1 cells [12].
  • The increases observed in phosphocholine and phosphomonoester levels suggest that these metabolites may have the potential to act as noninvasive pharmacodynamic markers for analyzing tumor response to treatment with 17AAG or other Hsp90 inhibitors [9].

Analytical, diagnostic and therapeutic context of Hsp84-2

  • RESULTS: Preclinical studies have demonstrated that disruption of many client proteins chaperoned by Hsp90 is achievable and associated with significant growth inhibition, both in vitro and in tumor xenografts [11].
  • Hsp90 client protein expression was determined by using western blots [9].
  • Hsp90 mRNA was cloned from a clinical isolate of C. albicans, converted to cDNA and cloned into vaccination plasmid pVAX1 [13].


  1. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. He, H., Zatorska, D., Kim, J., Aguirre, J., Llauger, L., She, Y., Wu, N., Immormino, R.M., Gewirth, D.T., Chiosis, G. J. Med. Chem. (2006) [Pubmed]
  2. Characterization of heat-inducible expression and cloning of HtpG (Hsp90 homologue) of Porphyromonas gingivalis. Lopatin, D.E., Combs, A., Sweier, D.G., Fenno, J.C., Dhamija, S. Infect. Immun. (2000) [Pubmed]
  3. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Aoyagi, S., Archer, T.K. Trends Cell Biol. (2005) [Pubmed]
  4. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox. Mahajan, N.P., Whang, Y.E., Mohler, J.L., Earp, H.S. Cancer Res. (2005) [Pubmed]
  5. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Vilenchik, M., Solit, D., Basso, A., Huezo, H., Lucas, B., He, H., Rosen, N., Spampinato, C., Modrich, P., Chiosis, G. Chem. Biol. (2004) [Pubmed]
  6. A role for the Hsp90 molecular chaperone family in antigen presentation to T lymphocytes via major histocompatibility complex class II molecules. Rajagopal, D., Bal, V., Mayor, S., George, A., Rath, S. Eur. J. Immunol. (2006) [Pubmed]
  7. Heat shock protein 90 suppresses tumor necrosis factor alpha induced apoptosis by preventing the cleavage of Bid in NIH3T3 fibroblasts. Zhao, C., Wang, E. Cell. Signal. (2004) [Pubmed]
  8. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Sanderson, S., Valenti, M., Gowan, S., Patterson, L., Ahmad, Z., Workman, P., Eccles, S.A. Mol. Cancer Ther. (2006) [Pubmed]
  9. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. Chung, Y.L., Troy, H., Banerji, U., Jackson, L.E., Walton, M.I., Stubbs, M., Griffiths, J.R., Judson, I.R., Leach, M.O., Workman, P., Ronen, S.M. J. Natl. Cancer Inst. (2003) [Pubmed]
  10. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. Llauger, L., He, H., Kim, J., Aguirre, J., Rosen, N., Peters, U., Davies, P., Chiosis, G. J. Med. Chem. (2005) [Pubmed]
  11. The Hsp90 chaperone complex as a novel target for cancer therapy. Goetz, M.P., Toft, D.O., Ames, M.M., Erlichman, C. Ann. Oncol. (2003) [Pubmed]
  12. N-acetyl-cysteine enhances growth in BCR-ABL-transformed cells. Zhang, Q., Tsukahara, F., Maru, Y. Cancer Sci. (2005) [Pubmed]
  13. Comparison of protective effect of protein and DNA vaccines hsp90 in murine model of systemic candidiasis. Raska, M., Beláková, J., Wudattu, N.K., Kafková, L., Růzicková, K., Sebestová, M., Kolár, Z., Weigl, E. Folia Microbiol. (Praha) (2005) [Pubmed]
WikiGenes - Universities